There is significant variability and underutilization of standard heart failure therapies like beta-blockers and ACE inhibitors at discharge for pediatric patients with acute decompensated heart failure.
Answers are grounded in this paper and cite their sources.
Substantial practice variation in pediatric ADHF warrants caution; leaves open optimal medication strategies pending prospective trials.
This is the first national evaluation of prescribing trends in pediatric ADHF medication. A large degree of variability in medication use for ADHF and low rates of beta-blocker and ACE inhibitor use at discharge were identified.
No takes yet. Share an insight, caveat, or question.
Moffett et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: